Patents by Inventor Joerg Moelleken

Joerg Moelleken has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for determining the in vivo interaction mode
    Patent number: 11958912
    Abstract: Herein is reported a method for determining the binding interaction with a multimeric antigen of an antibody of the human IgG1 subclass that has at least two binding sites specifically binding to the antigen comprising the steps of 1) determining the binding affinity of the antibody for the multimeric antigen, and 2) incubating a mixture comprising the antibody and a polypeptide that is derived from lysine-gingipain of Porphyromonas gingivalis under conditions and for a time sufficient to cleave the antibody into Fabs and Fc-region, and determining the binding affinity of the Fabs of the antibody for the multimeric, whereby the binding affinity of the antibody to the multimeric antigen to be affinity-driven if the binding affinity determined in both steps are comparable and to be avidity-driven if the binding affinity determined in both steps are different.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: April 16, 2024
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Joerg Moelleken, Michael Molhoj, Christian Gassner, Manuel Endesfelder, Joerg-Thomas Regula
  • BISPECIFIC ANTI-CCL2 ANTIBODIES
    Publication number: 20240117029
    Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.
    Type: Application
    Filed: November 14, 2023
    Publication date: April 11, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jens FISCHER, Guy GEORGES, Anton JOCHNER, Gregor JORDAN, Hubert KETTENBERGER, Joerg MOELLEKEN, Tilman SCHLOTHAUER, Georg TIEFENTHALER, Valeria RUNZA, Meher MAJETY, Martin SCHAEFER, Maria VIERT, Shu FENG, Wei Shiong Adrian HO, Siok Wan GAN, Runyi Adeline LAM, Michael GERTZ
  • ANTIBODY THAT BINDS TO VEGF AND IL-1BETA AND METHODS OF USE
    Publication number: 20240101657
    Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
    Type: Application
    Filed: November 15, 2023
    Publication date: March 28, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ROLAND BECKMANN, JOERG BENZ, STEFAN DENGL, CHRISTIAN GASSNER, GUIDO HARTMANN, PETER MICHAEL HUELSMANN, SABINE IMHOF-JUNG, KRISTIAN HOBOLT JENSEN, HUBERT KETTENBERGER, STEFAN LORENZ, JOERG MOELLEKEN, OLAF MUNDIGL
  • BISPECIFIC ANTI-CCL2 ANTIBODIES
    Publication number: 20240083993
    Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.
    Type: Application
    Filed: June 15, 2023
    Publication date: March 14, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jens FISCHER, Guy GEORGES, Anton JOCHNER, Gregor JORDAN, Hubert KETTENBERGER, Joerg MOELLEKEN, Tilman SCHLOTHAUER, Georg TIEFENTHALER, Valeria RUNZA, Meher MAJETY, Martin SCHAEFER, Maria VIERT, Shu FENG, Wei Shiong Adrian HO, Siok Wan GAN, Runyi Adeline LAM, Michael GERTZ
  • SPR-BASED BRIDGING ASSAY FORMAT FOR DETERMINING THE BIOLOGICAL ACTIVITY OF MULTIVALENT, MULTISPECIFIC MOLECULES
    Publication number: 20240077495
    Abstract: Herein is reported the use of a binding assay of a bivalent, bispecific antibody that has the smaller kD value (dissociation constant) for the interaction with its antigen for the immobilization of the bivalent, bispecific antibody to a solid surface for the determination of the biological activity of the bivalent, bispecific antibody.
    Type: Application
    Filed: April 4, 2023
    Publication date: March 7, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Apollon Papadimitriou, Joerg Thomas Regula, Hubert Kettenberger, Joerg Moelleken, Christian Gassner
  • Antibody that binds to VEGF and IL-1beta and methods of use
    Patent number: 11866490
    Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
    Type: Grant
    Filed: September 8, 2021
    Date of Patent: January 9, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roland Beckmann, Joerg Benz, Stefan Dengl, Christian Gassner, Guido Hartmann, Peter Michael Huelsmann, Sabine Imhof-Jung, Kristian Hobolt Jensen, Hubert Kettenberger, Stefan Lorenz, Joerg Moelleken, Olaf Mundigl
  • ANTIBODY THAT BINDS TO VEGF-A AND ANG2 AND METHODS OF USE
    Publication number: 20230374119
    Abstract: The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.
    Type: Application
    Filed: June 22, 2023
    Publication date: November 23, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Roland Beckmann, Sebastian Fenn, Guido Hartmann, Sabine lmhof-Jung, Kristian Hobolt-Jensen, Joerg Moelleken, Michael Molhoj, Christian Schantz, Janina Speck, Christoph UlImer, Barbara Weiser
  • Anti-VEGF antibodies and methods of use
    Patent number: 11820816
    Abstract: The present invention relates to anti-VEGF antibodies and methods of their production and their use.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: November 21, 2023
    Assignee: Hoffman-La Roche Inc.
    Inventors: Stefan Dengl, Sebastian Fenn, Guy Georges, Joerg Moelleken, Francesca Ros, Esther Koenigsberger
  • Bispecific anti-CCL2 antibodies
    Patent number: 11739142
    Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: August 29, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jens Fischer, Guy Georges, Anton Jochner, Gregor Jordan, Hubert Kettenberger, Joerg Moelleken, Tilman Schlothauer, Georg Tiefenthaler, Valeria Runza, Meher Majety, Martin Schaefer, Maria Viert, Shu Feng, Wei Shiong Adrian Ho, Siok Wan Gan, Runyi Adeline Lam, Michael Gertz
  • HUMANIZED ANTI-TAU(PS422) ANTIBODIES AND METHODS OF USE
    Publication number: 20230265177
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Application
    Filed: December 29, 2022
    Publication date: August 24, 2023
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • Antibody that binds to VEGF-A and ANG2 and methods of use
    Patent number: 11732036
    Abstract: The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: August 22, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roland Beckmann, Sebastian Fenn, Guido Hartmann, Sabine Imhof-Jung, Kristian Hobolt-Jensen, Joerg Moelleken, Michael Molhoj, Christian Schantz, Janina Speck, Christoph Ullmer, Barbara Weiser
  • SPR-based dual-binding assay for the functional analysis of multispecific molecules
    Publication number: 20230236178
    Abstract: Herein is reported a method for determining the binding of an antibody, which comprises a first binding site specifically binding to a first antigen and a second binding site specifically binding to a second antigen, to said first and said second antigen, wherein the method comprises the steps of capturing the antibody on a solid phase using a capture reagent specifically binding to a constant domain of the antibody, incubating the captured antibody with the first or the second antigen to form a captured antibody-antigen complex and determining a first binding signal, either i) incubating the captured antibody-antigen complex with the antigen not used for the formation of the captured antibody-antigen complex to form a captured antibody-antigen-antigen complex and determining a second binding signal, or ii) regenerating the surface, capturing the antibody on a solid phase using a capture reagent specifically binding to a constant domain of the antibody, incubating the captured antibody with the antigen not us
    Type: Application
    Filed: August 22, 2022
    Publication date: July 27, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian Gassner, Wolfgang Meschendoerfer, Joerg Moelleken
  • Humanized anti-Tau(pS422) antibodies and methods of use
    Patent number: 11572404
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: February 7, 2023
    Assignee: Hoffman-La Rocher Inc.
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • ANTIBODIES FOR CHELATED RADIONUCLIDES
    Publication number: 20220389116
    Abstract: The present application relates to antibodies which bind specifically to chelated radionuclides, including bispecific antibodies. It further relates to the use of such bispecific antibodies in applications such as radioimmunoimaging and radioimmunotherapy. It additionally relates to clearing agents and compositions useful in such methods. The chelated radionuclides may be a DOTAM-lead (Pb) chelate.
    Type: Application
    Filed: April 16, 2019
    Publication date: December 8, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian KLEIN, Pablo UMANA, Alexander HAAS, Barbara WEISER, Florian LIPSMEIER, Guy GEORGES, Sebastian FENN, Joerg MOELLEKEN, Felix BORMANN, Daniela MATSCHEKO
  • ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS
    Publication number: 20220267463
    Abstract: The present invention relates to antibodies which bind to antigens on target cells and which target radionuclides to said cells, and to methods of using the same.
    Type: Application
    Filed: July 10, 2020
    Publication date: August 25, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Pablo UMANA, Sabine IMHOF-JUNG, Alexander HAAS, Christian KLEIN, Sofia FROST, Felix BORMANN, Guy GEORGES, Sebastian FENN, Florian LIPSMEIER, Daniela MATSCHEKO, Joerg MOELLEKEN, Barbara WEISER
  • ANTIBODY THAT BINDS TO VEGF-A AND ANG2 AND METHODS OF USE
    Publication number: 20220073599
    Abstract: The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.
    Type: Application
    Filed: September 3, 2021
    Publication date: March 10, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Roland Beckmann, Sebastian Fenn, Guido Hartmann, Sabine Imhof-Jung, Kristian Hobolt-Jensen, Joerg Moelleken, Michael Molhoj, Christian Schantz, Janina Speck, Christoph Ullmer, Barbara Weiser
  • ANTIBODY THAT BINDS TO VEGF AND IL-1BETA AND METHODS OF USE
    Publication number: 20220041707
    Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
    Type: Application
    Filed: September 8, 2021
    Publication date: February 10, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ROLAND BECKMANN, JOERG BENZ, STEFAN DENGL, CHRISTIAN GASSNER, GUIDO HARTMANN, PETER MICHAEL HUELSMANN, SABINE IMHOF-JUNG, KRISTIAN HOBOLT JENSEN, HUBERT KETTENBERGER, STEFAN LORENZ, JOERG MOELLEKEN, OLAF MUNDIGL
  • METHOD FOR IMPROVING INHIBITION OF VEGF-BINDING TO VEGF-R1 OF AN ANTI-VEGF ANTIBODY
    Publication number: 20220002397
    Abstract: The present invention relates to methods for modulating anti-VEGF antibodies in order to provide variants of an anti-VEGF antibody that exhibit improved inhibition of VEGF binding to VEGF-R1; and antibodies provided by said methods.
    Type: Application
    Filed: June 17, 2021
    Publication date: January 6, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg Benz, Stefan Dengl, Andreas Ehler, Sebastian Fenn, Joerg Moelleken
  • Antibodies specific for DR5 and methods of use
    Patent number: 11214622
    Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: January 4, 2022
    Assignee: ROCHE GLYCART AG
    Inventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, Inja Waldhauer, Huisheng Wang, Barbara Weiser
  • Antibody that binds to VEGF and IL-1beta and methods of use
    Patent number: 11130804
    Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: September 28, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roland Beckmann, Joerg Benz, Stefan Dengl, Christian Gassner, Guido Hartmann, Peter Michael Huelsmann, Sabine Imhof-Jung, Kristian Hobolt Jensen, Hubert Kettenberger, Stefan Lorenz, Joerg Moelleken, Olaf Mundigl